The corticosteroid methylprednisolone is detected at low, safe levels in the breast milk of women with multiple sclerosis (MS) during and after intravenous (into-the-vein) treatment for a postpartum relapse, according to a small study in Turkey.
While these findings suggest that women can safely breastfeed their child during and shortly after a methylprednisolone infusion, the researchers recommended they wait two to four hours after treatment to further limit the baby’s exposure.
The study, “Methylprednisolone Concentrations in Breast Milk and Serum of Patients with Multiple Sclerosis Treated with IV Pulse Methylprednisolone,” was published in the journal Clinical Neurology and Neurosurgery.
Women with MS are at increased risk of a relapse after giving birth (postpartum period). High-dose intravenous methylprednisolone is used as a first-line treatment for acute relapses of MS, but data on its safety during breastfeeding remain limited.
A previous Turkish study in 16 women with MS suggested that the transfer of methylprednisolone into breast milk was very low, leading to a relative infant dose (RID) of 0.71%, well below the generally acceptable RID value of less than 10%. RID estimates an infant’s exposure to a medication via breast milk.
Now, researchers involved in that study set out to further analyze the association between methylprednisolone levels in blood and breast milk of women with MS during and after treatment administration.
The study included 12 breastfeeding women with MS (mean age, 28.03) being treated for postpartum relapse with a 1,000 mg methylprednisolone infusion (given over one hour) for three or five consecutive days.
These women had a mean disease duration of 3.59 years and minimal disability, as shown by a mean score of 1.5 on the expanded disability status scale — a method of quantifying disability in MS, with higher scores indicating greater disability.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?